Three-drug combo for first-line pancreatic cancer treatment
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for people with pancreatic cancer that has not spread to the brain. It aims to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic cancer (confirmed by biopsy or cytology).
- You have not had chemotherapy for this cancer before (or if you had adjuvant therapy, it ended more than 6 months ago).
- You are in good enough health to be up and about (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within safe ranges (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This trial tests a new liposomal form of irinotecan in combination with other drugs as a second or later treatment for people with advanced pancreatic cancer that continued to grow after prior irinotecan therapy. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination of anlotinib (a targeted drug), benmelstobart (an immunotherapy), and AG chemotherapy as a first treatment for advanced pancreatic cancer that has spread to other parts of the body. The goal is to see if this triple therapy can help shrink or control the cancer better than standard treatments.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.